Profound Medical Exceeds 2025 TULSA-PRO Installation Target and Grows Sales Pipeline
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Profound Medical ( (TSE:PRN) ) has shared an announcement.
Profound Medical reported that it exceeded its 2025 goal for TULSA-PRO installations, ending the year with 78 systems deployed versus a target of 75, and disclosed a qualified sales pipeline of 97 additional systems in advanced stages of the sales process. Management highlighted that the expanding installed base is expected to drive higher patient treatment volumes and growth in high-margin recurring revenue, reinforcing the TULSA Procedure’s positioning as a versatile, incision-free option across the prostate disease spectrum and underscoring Profound’s strengthening commercial traction ahead of its upcoming fourth-quarter and full-year 2025 financial results.
The most recent analyst rating on (TSE:PRN) stock is a Hold with a C$12.50 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Spark’s Take on TSE:PRN Stock
According to Spark, TipRanks’ AI Analyst, TSE:PRN is a Neutral.
The score is held back primarily by persistent heavy losses and large cash burn despite strong revenue growth and improving gross margins. Technicals are supportive with a clear uptrend, and recent earnings commentary and events point to improving commercial traction and strengthened liquidity, but financing/dilution risk and lack of profitable valuation anchors keep the overall score in the mid-range.
To see Spark’s full report on TSE:PRN stock, click here.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. Its flagship TULSA-PRO system delivers the TULSA Procedure, a minimally invasive, one-session, ultrasound-based treatment designed to address the full spectrum of prostate disease while preserving urinary continence and sexual function, and is cleared or approved in major markets including the U.S., Europe and Canada. The company is also commercializing Sonalleve, a non-invasive therapeutic platform for indications such as uterine fibroids, adenomyosis, bone metastasis pain, desmoid tumors and osteoid osteoma, with ongoing exploration of additional oncology and hyperthermia applications.
Average Trading Volume: 18,845
Technical Sentiment Signal: Buy
Current Market Cap: C$427.5M
For an in-depth examination of PRN stock, go to TipRanks’ Overview page.
